{"entity":{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","aka":[],"tldr":"Some new medicines reprogramme immune cells inside the body with an injection, skipping the factory entirely. Test whether that makes CAR-T affordable and available in ordinary hospitals.","summary":"In vivo CAR-T uses targeted lipid nanoparticles or engineered lentiviral vectors to deliver the CAR gene to T cells inside the patient (programmes from Interius, Umoja, Orna, Capstan and others entered the clinic in 2024-25). This idea is not about which antigen to hit but about manufacturing and delivery economics: a frozen vial produced in batches of thousands, administered in a community hospital with no apheresis, no bridging chemotherapy and possibly no lymphodepletion. A companion idea in this corpus covers solid-tumour antigens.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":["idea-in-vivo-car-solid"],"cancers":["dlbcl"],"sections":[],"technologies":["in-vivo-car-t","car-t"],"targets":["cd19"],"drugs":[],"companies":["interius","umoja-biopharma","orna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04094311","reliance","talicel-phase-1-2","zuma-1","zuma-7"],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":["paper-hernandez-jama-oncol","paper-cd19-dlbcl-am-j-hematol-2021","paper-cd19-dlbcl-clin-cancer-res-2011","paper-cd19-dlbcl-cytotherapy-2020"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An in vivo CD19 CAR-T product can be produced at a cost of goods below $10,000 per dose and delivered in non-academic centres with complete response rates in relapsed B-cell lymphoma within 15 percentage points of autologous CAR-T, and with a shorter time from decision to treatment.","rationale":"Batch manufacture of a nucleic acid-lipid product is the same industrial process that produced billions of mRNA vaccine doses; the marginal cost is orders of magnitude below a bespoke cell product, and the logistics collapse to a cold chain.","test":"Phase 2 in relapsed large B-cell lymphoma at community and academic sites, with pre-specified endpoints for cost of goods, time from enrolment to infusion, and response rate; compare with matched autologous CAR-T recipients.","maturity":"early-clinical","actor":"industry","cost":"large","horizonYears":4},"route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","neighbours":{"idea":[{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/"},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/"},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/"}],"trial":[{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/"},{"id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/"},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}],"paper":[{"id":"paper-cd19-dlbcl-am-j-hematol-2021","kind":"paper","name":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","route":"/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/"},{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/"},{"id":"paper-cd19-dlbcl-cytotherapy-2020","kind":"paper","name":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","route":"/key-papers/paper-cd19-dlbcl-cytotherapy-2020/"},{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}